Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial reported that intensive glucose control prevents end-stage kidney disease (ESKD) in patients with type 2 diabetes, but uncertainty about the balance between risks and benefits exists. Here, we examine the long-term effects of intensive glucose control on risk of ESKD and other outcomes. RESEARCH DESIGN AND METHODS: Survivors, previously randomized to intensive or standard glucose control, were invited to participate in post-trial follow-up. ESKD, defined as the need for dialysis or kidney transplantation, or death due to kidney disease, was documented overall and by baseline CKD stage, along with hypoglycemic episodes, major cardiovascular events, and death from other causes. RESULTS: A total of 8,494 ADVANCE participants were followed for a median of 5.4 additional years. In-trial HbA1c differences disappeared by the first post-trial visit. The in-trial reductions in the risk of ESKD (7 vs. 20 events, hazard ratio [HR] 0.35, P = 0.02) persisted after 9.9 years of overall follow-up (29 vs. 53 events, HR 0.54, P < 0.01). These effects were greater in earlier-stage CKD (P = 0.04) and at lower baseline systolic blood pressure levels (P = 0.01). The effects of glucose lowering on the risks of death, cardiovascular death, or major cardiovascular events did not differ by levels of kidney function (P > 0.26). CONCLUSIONS: Intensive glucose control was associated with a long-term reduction in ESKD, without evidence of any increased risk of cardiovascular events or death. These benefits were greater with preserved kidney function and with well-controlled blood pressure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, there is a lag time of at least 2 years in type 2 diabetes to over 10 years in type 1 diabetes for the effects of intensive glucose control to manifest as improved eGFR outcomes (57,61,62).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [62]
In the citing paper
“Moreover, there is a lag time of at least 2 years in type 2 diabetes to over 10 years in type 1 diabetes for the effects of intensive glucose control to manifest as improved eGFR outcomes (59)(60)(61).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [61]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Post-trial follow-up of the UK Prospective Diabetes Study (UKPDS) cohort of newly diagnosed patients with type 2 diabetes (7) and the Diabetes Control and Complications Trial (DCCT) cohort of young patients with type 1 diabetes (8) showed a sustained benefit for microvascular complications, beyond the period of intens…”
BackgroundSelf-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“Despite the implementation of “best practice” standards of care for lifestyle modification, blood pressure lowering, and renin-angiotensin-aldosterone system blockade, there remains a high level of progression to ESKD for those with diabetic kidney disease (4,5).”
BackgroundSelf-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 2×
“Despite the implementation of ‘best practice’ standards of care for lifestyle modification, blood pressure lowering and renin-angiotensin-aldosterone system (RAAS) blockade, there remains a high level of progression to ESKD for those with diabetic kidney disease (4, 5).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Andrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
Worldwide access to treatment for end-stage kidney disease: a systematic review
Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M.-H., Lv, J., Garg, A. X., Knight, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61601-9 · Cited by 2,339
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Cited by
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Self-citationCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationDiabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
“20 Past hyperglycemia leads to long-lasting advanced glycation end products and epigenetic modifications, as well as subsequent upregulation of proinflammatory and profibrotic genes.”
BackgroundGlobal kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J.-A., Fogo, A. B., Fox, C. S., Gansevoort, R. T., Heerspink, H. J. L., Jardine, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30788-2 · Cited by 919
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30141-4 · Cited by 637
Self-citation11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
“cose control to manifest as improved eGFR outcomes (49,54,55).”
Background11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
“type 2 diabetes to over 10 years in type 1 diabetes for the effects of intensive glucose control to manifest as improved eGFR outcomes (33,37,38).”
Background11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s010 · Cited by 302
“over, there is a lag time of at least 2 years in type 2 diabetes to over 10 years in type 1 diabetes for the effects of intensive glucose control to manifest as improved eGFR outcomes (31,35,36).”
Background11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 289
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s011 · Cited by 275
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
Uric acid and inflammation in kidney disease
Jung, S. W., Kim, S.-M., Kim, Y. G., Lee, S.-H., & Moon, J.-Y. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00272.2019 · Cited by 190
“Given that kidney fibrosis is an inevitable consequence of sustained inflammation, fibrosis markers (transforming growth factor- , collagen, and -smooth muscle actin) are also improved by the use of XO inhibitors in murine models of DKD (61, 62, 70).”
BackgroundInfluential10. Microvascular Complications and Foot Care
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s013 · Cited by 181
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
Kawanami, D., Matoba, K., Takeda, Y., Nagai, Y., Akamine, T., Yokota, T., Sango, K., & Utsunomiya, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051083 · Cited by 168
“Recently, the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation Post-Trial Observational Study (ADVANCE-ON) demonstrated the long-term benefits of intensive glycemic control for preventing ESRD in patients with T2D [3].”
BackgroundPerkovic, V., Agarwal, R., Fioretto, P., Hemmelgarn, B. R., Levin, A., Thomas, M. C., Wanner, C., Kasiske, B. L., Wheeler, D. C., Groop, P.-H., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.010 · Cited by 136
Self-citation2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E., Budzyński, A., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G., Dziedzic, T., Franek, E., et al. (2019) · Clinical Diabetology · doi:10.5603/dk.2019.0001 · Cited by 123
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Mende, C. W. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01994-2 · Cited by 147
“73 m(2) and systolic BP (SBP)\ 140 mmHg [54].”
BackgroundOellgaard, J., Gæde, P., Rossing, P. R., Persson, F., Parving, H., & Pedersen, O. B. (2017) · Kidney International · doi:10.1016/j.kint.2016.11.023 · Cited by 124
“Furthermore, initially observed relative risk reductions with antihypertensive treatment or intensive glucose-lowering treatment were not sustained after cessation of the intervention.(12,13) A recently published meta-analysis built on modeled data showed the beneficial effects of early initiation compared with late i…”
Kanasaki, K. (2018) · Clinical Science · doi:10.1042/cs20180031 · Cited by 117
Meneilly, G. S., Knip, A., Miller, D. B., Sherifali, D., Tessier, D., & Zahedi, A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.021 · Cited by 144
Glucose targets for preventing diabetic kidney disease and its progression
Ruospo, M., Saglimbene, V. M., Palmer, S. C., De Cosmo, S., Pacilli, A., Lamacchia, O., Cignarelli, M., Fioretto, P., Vecchio, M., Craig, J. C., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010137.pub2 · Cited by 111
New pharmacological strategies for protecting kidney function in type 2 diabetes
Muskiet, M. H. A., Wheeler, D. C., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30263-8 · Cited by 107
Effects of glycaemic management on diabetic kidney disease
MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i5.172 · Cited by 118
Sex and gender differences in therapy of type 2 diabetes
Kautzky‐Willer, A., & Harreiter, J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.07.012 · Cited by 117
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
Self-citationCardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD
Navaneethan, S. D., Schold, J. D., Jolly, S. E., Arrigain, S., Winkelmayer, W. C., & Nally, J. V. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.11.018 · Cited by 79
Ling, J., Ng, J. K., Chan, J. C. N., & Chow, E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.869899 · Cited by 88
Prattichizzo, F., de Candia, P., & Ceriello, A. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154799 · Cited by 82
Renal physiology of glucose handling and therapeutic implications
Cherney, D. Z. I., Kanbay, M., & Lovshin, J. A. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz230 · Cited by 73
“In contrast, protective effects on ‘hard’ renal endpoints such as end-stage kidney disease have been relatively limited to long-term follow-up of the ADVANCE-ON trial—a benefit that was seen beyond the duration of the trial [3].”
BackgroundEfficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment
Cherney, D. Z. I., Ferrannini, E., Umpierrez, G. E., Peters, A. L., Rosenstock, J., Carroll, A. K., Lapuerta, P., Banks, P. L., & Agarwal, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14513 · Cited by 73
2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 85
Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
Dai, Z.-C., Chen, J., Zou, R., Liang, X.-B., Tang, J., & Yao, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213473 · Cited by 84
Colagiuri, S., Matthews, D. R., Leiter, L. A., Chan, S. P., Sesti, G., & Marre, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.028 · Cited by 63
Self-citationA1C targets should be personalized to maximize benefits while limiting risks
Riddle, M. C., Gerstein, H. C., Holman, R. R., Inzucchi, S. E., Zinman, B., Zoungas, S., & Cefalu, W. T. (2018) · Diabetes Care · doi:10.2337/dci18-0018 · Cited by 54
Self-citationScheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.10.003 · Cited by 63
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
Mottl, A. K., Buse, J. B., Ismail-Beigi, F., Sigal, R. J., Pedley, C. F., Papademetriou, V., Simmons, D. L., Katz, L., Mychaleckyj, J. C., & Craven, T. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06200518 · Cited by 48
“Discrepant findings from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, a cohort more similar to that of the ACCORD trial, are more difficult to explain (11,31).”
2018 Guidelines on the management of diabetic patients. A position of Diabetes Poland
Diabetology, C. (2018) · Clinical Diabetology · doi:10.5603/dk.2018.0001 · Cited by 52
Mineralocorticoid Antagonism and Diabetic Kidney Disease
Lytvyn, Y., Godoy, L. C., Scholtes, R. A., van Raalte, D. H., & Cherney, D. Z. I. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1123-8 · Cited by 52
The legacy effect in diabetes: are there long-term benefits?
Folz, R., & Laiteerapong, N. (2021) · Diabetologia · doi:10.1007/s00125-021-05539-8 · Cited by 46
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 45
Management of type 2 diabetes in chronic kidney disease
Triozzi, J. L., Gregg, L. P., Virani, S. S., & Navaneethan, S. D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002300 · Cited by 51
“21 A post hoc analysis of the Steno-2 study suggested that intensive glycemic control, as part of a multifactorial behavioral and pharmacological intervention, slows eGFR decline and reduces ESKD and death.”
Crawford, A. L., & Laiteerapong, N. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202406180 · Cited by 54
Vanholder, R. C., Laecke, S. V., Glorieux, G., Verbeke, F., Castillo-Rodríguez, E., & Ortíz, A. (2018) · Toxins · doi:10.3390/toxins10060237 · Cited by 48
“The SGLT-2 inhibitors are a promising addition to our therapeutic arsenal especially for moderate CKD (Table 5, part A) and may offer novel pathways to protect kidneys, which hopefully will be corroborated by ongoing dedicated studies in diabetic and non-diabetic CKD assessing long-term and hard outcomes, including ev…”
InfluentialAlkaff, F. F., Illavi, F., Salamah, S., Setiyawati, W., Ramadhani, R., Purwantini, E., & Tahapary, D. L. (2021) · Journal of Primary Care & Community Health · doi:10.1177/2150132720984409 · Cited by 88
Glycemic Control as Primary Prevention for Diabetic Kidney Disease
MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.11.003 · Cited by 47
Huh, J. H., Ahn, S. G., Kim, Y. I., Go, T., Sung, K.-C., Choi, J. H., Koh, K. K., & Kim, J. Y. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0111 · Cited by 42
Novel therapies for diabetic kidney disease
Cherney, D. Z. I., & Bakris, G. L. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.005 · Cited by 48
“From a renal perspective, the Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post-Trial Observational Study (ADVANCE-ON) reported that while there were no effects on cardiovascular outcomes or mortality, intensive glycemic control reduced the risk of microvascular complications…”
BackgroundCardoso, C. R. L., Leite, N. C., Salles, G. C., Ferreira, M. T., & Salles, G. F. (2017) · Diabetologia · doi:10.1007/s00125-017-4484-z · Cited by 42
Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.1487 · Cited by 39
Rossing, P., Burgess, E., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Gillard, P., MacIsaac, R. J., Wainstein, J., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1944 · Cited by 44
Self-citationKang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Strict blood pressure control associates with decreased mortality risk by APOL1 genotype
Ku, E., Lipkowitz, M. S., Appel, L. J., Parsa, A., Gassman, J., Glidden, D. V., Smogorzewski, M. J., & Hsu, C. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.033 · Cited by 38
Long-term impact of bariatric surgery in diabetic nephropathy
Young, L. H., Hanipah, Z. N., Brethauer, S. A., Schauer, P. R., & Aminian, A. (2018) · Surgical Endoscopy · doi:10.1007/s00464-018-6458-8 · Cited by 37
Abdelhafiz, A. H., & Sinclair, A. J. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107639 · Cited by 40
Khoo, C. M., Deerochanawong, C., Chan, S. P., Matawaran, B. J., Sheu, W. H., Chan, J. C. N., Mithal, A., Luk, A. O. Y., Suastika, K., Yoon, K., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14251 · Cited by 41
“Now, we have the evidence of the efficacy and safety of SGLT-2 inhibitors with regard to renal outcomes in patients with CKD with or without T2D.”
BackgroundInfluentialPresent and future directions in diabetic kidney disease
Limonte, C. P., Kretzler, M., Pennathur, S., Pop‐Busui, R., & de Boer, I. H. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108357 · Cited by 39
Naser, A. Y., Alwafi, H. H., Alotaibi, B. J., Salawati, E. M., Samannodi, M. S., Alsairafi, Z. K., Alanazi, A. F. R., & Dairi, M. S. (2021) · International Journal of Endocrinology · doi:10.1155/2021/4572743 · Cited by 44
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
Huang, W., Chen, Y., Li, Z., He, F., & Zhang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810882 · Cited by 36
“Furthermore, one observational study further validated that intensive glycemic control could reduce the risk of developing ESRD, especially in patients with preserved renal function [32].”
BackgroundCardiovascular Protection with Anti-hyperglycemic Agents
DEEDWANIA, P. C., & Acharya, T. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00325-9 · Cited by 33
De Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 31
“122 Moreover, the effects of glucose lowering on the risks of death, CV death, or MACEs did not differ by levels of kidney function.”
The prevention and management of chronic kidney disease among patients with metabolic syndrome
Zhu, D., Judge, P. K., Wanner, C., Haynes, R., & Herrington, W. G. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.021 · Cited by 36
Cardiovascular outcome trials of the newer anti-diabetic medications
Acharya, T., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.08.003 · Cited by 31
Ismail‐Beigi, F., Moghissi, E. S., Kosiborod, M., & Inzucchi, S. E. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4061-7 · Cited by 28
Wu, Y.-L., Wu, Y., Akhmetzhanov, A. R., Wu, M., Lin, Y.-F., & Lin, C. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-082959 · Cited by 37
Evaluation of Serum Glucose and Kidney Disease Progression Among Patients With Diabetes
Jung, H. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.27387 · Cited by 30
Anand, S., Kondal, D., Montez‐Rath, M. E., Zheng, Y., Shivashankar, R., Singh, K., Gupta, P., Gupta, R., Ajay, V. S., Mohan, V., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173554 · Cited by 28
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease
Jiménez, D. L., Cherney, D. Z. I., Bjornstad, P., Castilla‐Guerra, L., & Miramontes‐González, J. P. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00384.2017 · Cited by 27
Shikata, K., Haneda, M., Ninomiya, T., Koya, D., Suzuki, Y., Suzuki, D., Ishida, H., Akai, H., Tomino, Y., Uzu, T., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13339 · Cited by 24
ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE
Liew, A., Bavanandan, S., Prasad, N., Wong, M. G., Chang, J. M., Eiam‐Ong, S., Hao, C., Lim, C. Y., Lim, S. K., Oh, K., et al. (2020) · Nephrology · doi:10.1111/nep.13785 · Cited by 24
“Moreover, HbA1c accurately relates the degree of glycaemic control to death and DM associated morbidity (164).”
BackgroundSelf-citationLee, S. J., Lee, H., Oh, H. J., Go, T., Kang, D. R., Kim, J., & Huh, J. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-29958-7 · Cited by 25
Perco, P., Pena, M. J., Heerspink, H. J. L., & Mayer, G. J. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.12.001 · Cited by 26
Abdelhafiz, A. H. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00773-y · Cited by 26
Diabetic kidney disease in children and adolescents: an update
Lopez, L. N., Wang, W., Loomba, L. A., Afkarian, M., & Butani, L. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-05347-7 · Cited by 31
“, VADT [50], ADVANCE [51]) and some have shown harm (ACCORD [52]).”
BackgroundThe Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm
Mohan, V., Cooper, M. E., Matthews, D. R., & Khunti, K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0573-y · Cited by 26
Self-citationChiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
Al‐Saleh, Y., Sabico, S., Al-Furqani, A., Jayyousi, A., Alromaihi, D., Ba-Essa, E. M., Alawadi, F., Alkaabi, J., Hassanein, M. M., Alsifri, S. N., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01059-1 · Cited by 37
“Longterm ([ 5 years post-trial) observational followup studies also indicated a significant cumulative benefit (as much as 46%) in relation to endstage kidney disease (ESKD), suggesting that renal protection persisted long after the surviving participants returned to their usual care [38, 39].”
BackgroundGetting to the “Heart” of the Matter on Diabetic Cardiovascular Disease: “Thanks for the Memory”
Cefalu, W. T., Rosenstock, J., LeRoith, D., Blonde, L., & Riddle, M. C. (2016) · Diabetes Care · doi:10.2337/dc16-0405 · Cited by 21
“(7) comment on the longterm effects of intensive glucose control on the risk of end-stage kidney disease (ESKD) and other outcomes in the ADVANCE-ON follow-up to the ADVANCE trial, which studied high-risk patients quite early in the course of type 2 diabetes.”
BackgroundHeinl, R. E., Dhindsa, D. S., Mahlof, E. N., Schultz, W. M., Ricketts, J. C., Varghese, T., Esmaeeli, A., Allard‐Ratick, M., Millard, A. J., Kelli, H. M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.507 · Cited by 21
Wang, Y., Peng, X., Hu, J., Luo, T., Wang, Z., Cheng, Q., Mei, M., He, W., Peng, C. X., Ma, L., et al. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13174 · Cited by 21
“As a major microvascular complication of diabetes, diabetic kidney disease (DKD) is not only an important cause of end-stage renal disease but a high-risk factor of cardiovascular events and all-cause mortality in diabetic patients.(1) The pathogenesis of DKD has not yet been fully clarified, and the treatment of DKD…”
BackgroundSelf-citationClosing the gap between evidence and practice in chronic kidney disease
Jardine, M., Kasiske, B. L., Adu, D., Alrukhaimi, M. N., Ashuntantang, G., Basnet, S., Chailimpamontree, W., Craig, J. C., O'Donoghue, D. J., Perkovic, V., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.006 · Cited by 26
Self-citationCao, Y., Sun, G., Liu, R., Sun, A., Zhang, Q., Yang, L., Wang, L., Chao, X., Zhou, X., Zhang, S., et al. (2019) · Renal Failure · doi:10.1080/0886022x.2019.1655451 · Cited by 19
Cigarette smoke inhalation aggravates diabetic kidney injury in rats
Jiang, S., Do, V. Q., Sung, J. H., Lee, M., & Ha, H. (2019) · Toxicology Research · doi:10.1039/c9tx00201d · Cited by 25
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 25
Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 22
Chernikov, A. A., Severina, A. S., Shamhalova, M., & Shestakova, M. V. (2016) · Diabetes Mellitus · doi:10.14341/7674 · Cited by 19
Wong, F. N., Chua, K. H., Tan, J. A. M. A., Wong, C. M., & Kuppusamy, U. R. (2018) · PeerJ · doi:10.7717/peerj.4421 · Cited by 15
Winocour, P. H., Bain, S. C., Chowdhury, T. A., De, P., Pokrajac, A., Fogarty, D. G., Frankel, A., Banerjee, D., Wahba, M. M., & Dasgupta, I. (2018) · British Journal of Diabetes · doi:10.15277/bjd.2018.172 · Cited by 21
Metadata
- Authors
- Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., Mancia, G., Marre, M., Matthews, D., Neal, B., Poulter, N., Rodgers, A., Williams, B., & Zoungas, S.
- Affiliations
- The University of Sydney (AU)
- Baker Heart and Diabetes Institute (AU)
- Centre Hospitalier de l’Université de Montréal (CA)
- The Royal Melbourne Hospital (AU)
- National Health Service (GB)
- IRCCS Istituto Auxologico Italiano (IT)
- Hôpital Bichat-Claude-Bernard (FR)
- University of Oxford (GB)
- Imperial College London (GB)
- University College London (GB)
- Corresponding author
- Perkovic, Vlado
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-03-22
- Volume
- 39
- Issue
- 5
- Pages
- 694-700
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2309242694
- Semantic Scholar
- 0dde5dd296b76622b14c9be052e0e64aac7208f9
- Cited by
- 240
- References
- 19
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 19 · 2023: 23 · 2022: 28 · 2021: 27 · 2020: 23 · 2019: 21 · 2018: 37 · 2017: 24 · 2016: 11
- FWCI
- 31.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0509-10222, NF-SI-0514-10011)
- Medical Research Council (MC_PC_13090)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tight glycemic control, end-stage renal disease, type 2 diabetes, ADVANCE trial, post-trial follow-up, chronic kidney disease, HbA1c, hypoglycemia, cardiovascular events, cardiovascular mortality, blood pressure, long-term outcomes
- MeSH terms
- Aged, Antihypertensive Agents, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Drug Combinations, Female, Follow-Up Studies, Gliclazide, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Indapamide, Kidney Failure, Chronic, Male, Middle Aged, Treatment Outcome, Perindopril
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.